Reviews on Reproductive Biology and Medicine

A special issue of Reproductive Medicine (ISSN 2673-3897).

Deadline for manuscript submissions: 30 June 2024 | Viewed by 6498

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biology, University of Naples Federico II, Naples, Italy
Interests: antioxidative physiological defence; steroids and steroid receptors; antioxidants under steroid control; reproductive health assessment; reprotoxicity monitoring; endangered species and validation of non-destructive examination methods; biodiversity conservation microassays
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India
Interests: free radicals; antioxidants; cell death mechanisms; genotoxicity; ubiquitin pathway; phytochemicals; epigenetics; and non-coding RNA in reproductive, cancer biology and developing biomarkers and new modalities for treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

This Special Issue aims to publish high-quality review articles within the field of Reproductive Biology and Medicine. We kindly encourage all research groups covering relevant areas within the field of reproductive health to contribute up-to-date, full-length comprehensive reviews, highlighting the latest developments in their research field.

Distinguished researchers from all over the world will be invited to contribute to this Special Issue. Potential contributors/invited authors are kindly requested to submit a tentative title and a short abstract to our Editorial Office (reproductivemedicine@mdpi.com) for pre-evaluation. Please note that selected full papers will still be subjected to a thorough and rigorous peer review. All papers will be published on an ongoing basis. The papers will be published with full open access after peer review.

Prof. Dr. Giulia Guerriero
Dr. Kamla Kant Shukla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reproductive Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • review
  • reproductive biology
  • reproductive medicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1258 KiB  
Review
Recent Developments in In Vitro Spermatogenesis and Future Directions
by In Ki Cho and Charles A. Easley
Reprod. Med. 2023, 4(3), 215-232; https://doi.org/10.3390/reprodmed4030020 - 11 Sep 2023
Viewed by 3057
Abstract
Recent developments in stem cell technologies have made significant advancements in the field of in vitro gametogenesis. In vitro gametogenesis (IVG) is a promising technology where functional gametes (sperm or egg cells) can be generated from stem cells. Scientists have made continuous advancements [...] Read more.
Recent developments in stem cell technologies have made significant advancements in the field of in vitro gametogenesis. In vitro gametogenesis (IVG) is a promising technology where functional gametes (sperm or egg cells) can be generated from stem cells. Scientists have made continuous advancements in the field and successfully derived fully functional sperm from stem cells in mice. Two recent papers generated excitement in IVG by generating bi-maternal and bi-paternal mice from embryonic stem cells (ESCs) and pluripotent stem cells (PSCs). IVG is a promising technology with potential applications that include infertility treatment, fertility preservation, same-sex reproduction, bypassing oocyte depletion in women with advanced age, conservation biology, genetic disorder prevention, and research into human germ cell development. In vitro spermatogenesis (IVS) is the attempt to recreate the process of spermatogenesis in a culture system. Spermatogenesis is essential for male fertility and reproductive health, but it can be impaired by various factors such as genetic defects, environmental toxicants, infections, aging, or medical therapies. Spermatogenesis is a complex and highly regulated process involving multiple cell proliferation, differentiation, and maturation stages. The main challenges of IVS are to provide a suitable microenvironment that mimics the testis in vivo, to support the survival and development of all the cell types involved in spermatogenesis, and to achieve complete and functional spermatogenesis. Therefore, there is a great interest in developing methods to study spermatogenesis in vitro, both for basic research and clinical applications. This review covers recent developments in in vitro spermatogenesis in the past two years. Advances in tissue engineering and regenerative medicine have introduced techniques like ex vivo tissue culture and technologies such as bioreactors, microfluidic systems, and organoids. Bioreactors and microfluidic systems replicate physiological conditions for tissue and cell cultivation, while organoids model organ functionality. Meanwhile, scaffolds, made from various materials, provide essential structural support, guiding the growth and organization of cells into functional tissues. Full article
(This article belongs to the Special Issue Reviews on Reproductive Biology and Medicine)
Show Figures

Figure 1

18 pages, 395 KiB  
Review
The Management of Inflammatory Bowel Disease during Reproductive Years: An Updated Narrative Review
by Nariman Hossein-Javaheri, Michael Youssef, Yaanu Jeyakumar, Vivian Huang and Parul Tandon
Reprod. Med. 2023, 4(3), 180-197; https://doi.org/10.3390/reprodmed4030017 - 03 Aug 2023
Cited by 1 | Viewed by 2089
Abstract
Inflammatory bowel disease (IBD) frequently affects women of childbearing age and often coincides with pregnancy. With an increased incidence of IBD, gastroenterologists and obstetricians are more frequently involved in caring for women of reproductive age. While the development of novel therapies has allowed [...] Read more.
Inflammatory bowel disease (IBD) frequently affects women of childbearing age and often coincides with pregnancy. With an increased incidence of IBD, gastroenterologists and obstetricians are more frequently involved in caring for women of reproductive age. While the development of novel therapies has allowed for successful conception and pregnancy outcomes, many patients may hesitate to conceive due to concerns for presumed adverse IBD effects on maternal and fetal health. As such, a noticeable percentage of patients may choose voluntary childlessness. Indeed, active IBD carries a greater risk of adverse pregnancy outcomes, including a loss of pregnancy, preterm delivery, and emergent C-sections. However, those with a quiescent disease tend to have fewer pregnancy complications. Therefore, it is essential to achieve remission prior to conception to optimize pregnancy outcomes. Dedicated IBD and pregnancy clinics can greatly assist in improving patient knowledge and attitudes towards pregnancy; through individualized pre-conception counseling, education, and medication adherence, the risks of poor pregnancy outcomes can be minimized. Furthermore, it is important for healthcare providers to have a sufficient understanding of the medication safety and tools to measure the disease activity, while counseling patients during gestation and breastfeeding periods. This review article aims to provide the most recent evidence-based management methods for IBD during pregnancy. Full article
(This article belongs to the Special Issue Reviews on Reproductive Biology and Medicine)
Back to TopTop